RPG Life Sciences Limited has completed the strategic reorganization of its active pharmaceutical ingredients (API) business by transferring it to a wholly owned subsidiary, RPG Active Pharma (RPGAP). The move aims to sharpen focus on the high-value niche product segment and accelerate growth through specialized management and capital infusion.

The company announced the transaction details in an investor presentation dated September 2, 2026. The restructuring involves the creation of RPGAP as a dedicated vehicle for the API business, separating it from the formulations segment within the parent entity.

Strategic Restructuring and Partnership

RPG Life Sciences has partnered with InvAscent, a pharma-centric private equity firm, to drive value creation in the new subsidiary. Under the agreement, RPGLS retains a 60% stake in RPGAP, while InvAscent holds 40% following a primary issuance valued at approximately ₹243.33 crore.

InvAscent brings over two decades of experience in building businesses across formulations, APIs, healthcare delivery, and medtech. The firm manages assets under management (AUM) exceeding $850 million across four funds. The partnership is expected to facilitate growth capital, industry relationships, and synergies in product selection and M&A.

Expansion Through Acquisitions

To enhance its product portfolio and manufacturing capacity, RPGAP has entered into agreements for two significant acquisitions:

• Actis Generics: RPGAP will acquire 100% of Actis Generics, a fully backward-integrated manufacturer of APIs and complex intermediates based in Visakhapatnam, Andhra Pradesh. The consideration is approximately ₹80 crore, including net working capital. Actis specializes in anti-diabetic and cardiology molecules with established customer relationships.

• Raghava Life Sciences: Via a slump sale mechanism, RPGAP will acquire the factory, product portfolio, and customer relationships of Raghava Life Sciences. The consideration is approximately ₹135 crore, including net working capital. Raghava operates a state-of-the-art facility near Hyderabad with an installed capacity of 300 KL and a portfolio of 29 API molecules, of which 22 are commercialized.

Operational Highlights

The API business, previously operating from a facility in Navi Mumbai, reported external third-party sales of approximately ₹95.1 crore in FY26, in addition to captive sales to RPGLS for its formulations business. The business focuses on high-value, low-volume niche products insulated from price commoditization.

What the Numbers Show

The combined acquisition cost for Actis Generics and Raghava Life Sciences totals approximately ₹215 crore (₹80 crore + ₹135 crore). This figure represents roughly 88% of the ₹243.33 crore equity investment brought in by InvAscent. This alignment suggests that the new partner’s capital is being deployed almost entirely toward immediate capacity expansion and portfolio enhancement rather than general corporate purposes or debt reduction.

Future Outlook

RPGAP positions itself as a zero-debt company with sufficient liquidity for organic and inorganic growth. The subsidiary plans to leverage economies of scale through backward integration and process optimization. The manufacturing capacity is set to increase fourfold through these transactions, supporting a revenue potential of about ₹200 crore at full utilization levels for the Raghava facility alone.

RPG Life Sciences announced that its Board of Directors approved the acquisition of the Active Pharmaceutical Ingredients (API) and intermediates business of Raghava Life Sciences Private Limited on September 2, 2026. The transaction is valued at up to ₹135 crore and will be executed by its wholly owned subsidiary, RPG Active Pharma Limited (RPGAP), through a slump sale.

The deal marks the second strategic move by RPGAP to build a scaled, integrated API organization, following the recent purchase of Actis Generics. The acquisition is structured as a going-concern transfer and requires regulatory approvals from local authorities before closing. Management expects the transaction to complete tentatively within 30 days or as mutually agreed, subject to satisfaction of closing conditions.

Asset Profile and Capacity

Raghava Life Sciences operates a manufacturing facility near Hyderabad spread across approximately 9 acres. The plant holds an installed capacity of around 300 KL and is approved under both WHO-GMP and EU-GMP standards. The asset includes a dedicated R&D setup and has seen significant investment in capacity expansion in recent years.

The acquired portfolio comprises 29 API molecules, including 22 commercialized APIs and 7 development-stage assets. These products span therapeutic segments including diabetes, cardiovascular, and central nervous system (CNS) disorders. The business holds multiple international regulatory credentials, including CEP, EU Written Confirmation, and KDMF approvals. The target business reported revenues of about ₹19 crore in FY26 (unaudited).

Strategic Rationale

RPGAP aims to unlock value through synergies across this acquisition, the Actis Generics business, and its wider network. Expected levers include backward integration, improved capacity utilization, cost synergies, and selected product transfers. Management stated that stronger business development and wider market access are poised to improve cost competitiveness and enhance operating leverage over time.

The acquisition will be funded in line with the recent equity raise announced by RPGAP. It is not a related-party transaction, and the promoter group has no interest in the entity being acquired.

Leadership Commentary

Ashok Nair, Managing Director of RPG Life Sciences Limited, described the deal as an important addition that brings together a high-quality manufacturing asset and broad portfolio. He emphasized that the real opportunity lies in unlocking potential through stronger commercialization and integration across the organization.

Lohith Ponguleti, Managing Director of Raghava Life Sciences Private Limited, stated that the partnership positions the business to accelerate expansion across domestic and international markets.

Quillon Partners acted as legal advisors, o3 Capital as financial advisors, and Deloitte as the Financial Due Diligence partner for RPG Active Pharma Limited.